Tegafur/uracil

Drug Profile

Tegafur/uracil

Alternative Names: BMS 200604 01; Orzel; UFT; Uftoral

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Merck KGaA; Otsuka Pharmaceutical; Taiho Pharmaceutical
  • Class Antineoplastics; Nitrogen mustard compounds; Pyrimidinones
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 20 Jul 2005 Tegafur/Uracil has been licensed to Merck-KGaA worldwide
  • 06 Aug 2004 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 30 Apr 2004 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top